US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
JPS54113492A
(en)
|
1978-02-24 |
1979-09-05 |
Sanyo Chem Ind Ltd |
Preparation of glucoprotein derivative
|
US4356170A
(en)
|
1981-05-27 |
1982-10-26 |
Canadian Patents & Development Ltd. |
Immunogenic polysaccharide-protein conjugates
|
US4757006A
(en)
|
1983-10-28 |
1988-07-12 |
Genetics Institute, Inc. |
Human factor VIII:C gene and recombinant methods for production
|
US4970300A
(en)
|
1985-02-01 |
1990-11-13 |
New York University |
Modified factor VIII
|
US5250421A
(en)
|
1986-01-03 |
1993-10-05 |
Genetics Institute, Inc. |
Method for producing factor VIII:C-type proteins
|
US5198349A
(en)
|
1986-01-03 |
1993-03-30 |
Genetics Institute, Inc. |
Method for producing factor VIII:C and analogs
|
JPH0387173A
(en)
|
1987-09-10 |
1991-04-11 |
Teijin Ltd |
Preparation of human active natural type factor viii c and transformant using the same
|
US5153265A
(en)
|
1988-01-20 |
1992-10-06 |
Cetus Corporation |
Conjugation of polymer to colony stimulating factor-1
|
US4966999A
(en)
|
1988-06-07 |
1990-10-30 |
Cytogen Corporation |
Radiohalogenated compounds for site specific labeling
|
US5122614A
(en)
|
1989-04-19 |
1992-06-16 |
Enzon, Inc. |
Active carbonates of polyalkylene oxides for modification of polypeptides
|
SE465222C5
(en)
|
1989-12-15 |
1998-02-10 |
Pharmacia & Upjohn Ab |
A recombinant human factor VIII derivative and process for its preparation
|
SE466754B
(en)
|
1990-09-13 |
1992-03-30 |
Berol Nobel Ab |
COVALENT BINDING POLYMERS TO HYDROPHILIC SURFACES
|
US5492821A
(en)
|
1990-11-14 |
1996-02-20 |
Cargill, Inc. |
Stabilized polyacrylic saccharide protein conjugates
|
WO1992016555A1
(en)
|
1991-03-18 |
1992-10-01 |
Enzon, Inc. |
Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
|
US5846951A
(en)
|
1991-06-06 |
1998-12-08 |
The School Of Pharmacy, University Of London |
Pharmaceutical compositions
|
US6037452A
(en)
|
1992-04-10 |
2000-03-14 |
Alpha Therapeutic Corporation |
Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
|
AU5098193A
(en)
|
1992-09-01 |
1994-03-29 |
Berlex Laboratories, Inc. |
Glycolation of glycosylated macromolecules
|
WO1994007510A1
(en)
|
1992-10-02 |
1994-04-14 |
Kabi Pharmacia Ab |
Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
|
NZ250375A
(en)
|
1992-12-09 |
1995-07-26 |
Ortho Pharma Corp |
Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
|
US5298643A
(en)
|
1992-12-22 |
1994-03-29 |
Enzon, Inc. |
Aryl imidate activated polyalkylene oxides
|
WO1994015625A1
(en)
|
1993-01-15 |
1994-07-21 |
Enzon, Inc. |
Factor viii - polymeric conjugates
|
US5621039A
(en)
|
1993-06-08 |
1997-04-15 |
Hallahan; Terrence W. |
Factor IX- polymeric conjugates
|
SE504074C2
(en)
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Protein preparation for subcutaneous, intramuscular or intradermal administration
|
EP0792290B1
(en)
|
1993-09-17 |
2001-08-29 |
Novo Nordisk A/S |
Acylated insulin
|
US6011007A
(en)
|
1993-09-17 |
2000-01-04 |
Novo Nordisk A/S |
Acylated insulin
|
US6869930B1
(en)
|
1993-09-17 |
2005-03-22 |
Novo Nordisk A/S |
Acylated insulin
|
WO1996041813A2
(en)
|
1994-11-09 |
1996-12-27 |
Offord Robin E |
Functionalized polymers for site-specific attachment
|
WO1996040662A2
(en)
|
1995-06-07 |
1996-12-19 |
Cellpro, Incorporated |
Aminooxy-containing linker compounds and their application in conjugates
|
WO1996040731A1
(en)
|
1995-06-07 |
1996-12-19 |
Mount Sinai School Of Medicine Of The City University Of New York |
Pegylated modified proteins
|
SE9503380D0
(en)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
US5866538A
(en)
|
1996-06-20 |
1999-02-02 |
Novo Nordisk A/S |
Insulin preparations containing NaCl
|
AU7266898A
(en)
|
1997-04-30 |
1998-11-24 |
Enzon, Inc. |
Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
|
US6183738B1
(en)
|
1997-05-12 |
2001-02-06 |
Phoenix Pharamacologics, Inc. |
Modified arginine deiminase
|
WO1998055607A2
(en)
|
1997-06-04 |
1998-12-10 |
Oxford Biomedica (Uk) Limited |
Tumor targeted vector
|
WO1999003496A1
(en)
|
1997-07-21 |
1999-01-28 |
The University Of North Carolina At Chapel Hill |
Factor ix antihemophilic factor with increased clotting activity
|
ES2252876T5
(en)
|
1997-12-03 |
2014-04-03 |
Roche Diagnostics Gmbh |
Process to prepare polypeptides with adequate glycolization
|
US5985263A
(en)
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
US6596398B1
(en)
|
1998-08-21 |
2003-07-22 |
Atofina Chemicals, Inc. |
Solar control coated glass
|
CN1330675A
(en)
|
1998-08-28 |
2002-01-09 |
格莱风科学公司 |
Polyamide chains of precise length, methods to manufacture them and their conjugates with protein
|
ES2630278T3
(en)
|
1998-10-16 |
2017-08-21 |
Biogen Ma Inc. |
Interferon beta-1a polymer conjugates and uses thereof
|
DE19852729A1
(en)
|
1998-11-16 |
2000-05-18 |
Werner Reutter |
Recombinant glycoproteins, processes for their preparation, medicaments containing them and their use
|
CN100553678C
(en)
|
1999-02-22 |
2009-10-28 |
巴克斯特国际有限公司 |
The factor VIII formulations of new albumin-free
|
WO2000075105A1
(en)
*
|
1999-06-08 |
2000-12-14 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising aminooxy groups
|
US6531122B1
(en)
|
1999-08-27 |
2003-03-11 |
Maxygen Aps |
Interferon-β variants and conjugates
|
YU32402A
(en)
|
1999-11-12 |
2005-03-15 |
Maxygen Holdings Ltd. |
Interferon gamma conjugates
|
US7074878B1
(en)
|
1999-12-10 |
2006-07-11 |
Harris J Milton |
Hydrolytically degradable polymers and hydrogels made therefrom
|
US6413507B1
(en)
|
1999-12-23 |
2002-07-02 |
Shearwater Corporation |
Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
|
DE60138364D1
(en)
|
2000-02-11 |
2009-05-28 |
Bayer Healthcare Llc |
CLEANING FACTOR VII OR VIIA CONJUGATE
|
AU2001256148A1
(en)
|
2000-05-03 |
2001-11-12 |
Novo-Nordisk A/S |
Subcutaneous administration of coagulation factor vii
|
EP1282693B1
(en)
|
2000-05-03 |
2010-10-20 |
Novo Nordisk Health Care AG |
Human coagulation factor vii variants
|
AU2001268228A1
(en)
|
2000-06-08 |
2001-12-17 |
La Jolla Pharmaceutical Company |
Multivalent platform molecules comprising high molecular weight polyethylene oxide
|
US6423826B1
(en)
|
2000-06-30 |
2002-07-23 |
Regents Of The University Of Minnesota |
High molecular weight derivatives of vitamin K-dependent polypeptides
|
US7118737B2
(en)
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
HUP0301246A3
(en)
|
2000-09-13 |
2005-12-28 |
Novo Nordisk Healthcare Ag |
Human coagulation factor vii variants
|
BR0114374A
(en)
|
2000-10-02 |
2003-12-30 |
Novo Nordisk As |
Preparation comprising a plurality of factor vii polypeptides, methods for determining the pattern of factor vii glycoform and factor vii-related polypeptides, and for producing said preparation, pharmaceutical formulation, methods for treating a factor responsive syndrome. vii, for the prevention of unwanted bleeding, for the prevention of unwanted blood clotting, and for the prevention of tissue factor mediated reactions, and the use of the preparation.
|
GB0103877D0
(en)
*
|
2001-02-16 |
2001-04-04 |
King S College London |
Novel Drug Delivery system
|
EP1373493B1
(en)
|
2001-03-22 |
2013-07-31 |
Novo Nordisk Health Care AG |
Coagulation factor vii derivative
|
US6913915B2
(en)
|
2001-08-02 |
2005-07-05 |
Phoenix Pharmacologics, Inc. |
PEG-modified uricase
|
US6770625B2
(en)
*
|
2001-09-07 |
2004-08-03 |
Nobex Corporation |
Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
|
US7265084B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
NZ532027A
(en)
|
2001-10-10 |
2008-09-26 |
Neose Technologies Inc |
Remodeling and glycoconjugation of peptides
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
US7026440B2
(en)
|
2001-11-07 |
2006-04-11 |
Nektar Therapeutics Al, Corporation |
Branched polymers and their conjugates
|
EP1461445B1
(en)
|
2001-11-28 |
2008-08-20 |
Neose Technologies, Inc. |
Glycoprotein remodeling using endoglycanases
|
CA2468230A1
(en)
|
2001-11-28 |
2003-06-05 |
Neose Technologies, Inc. |
Glycopeptide remodeling using amidases
|
DK1517710T3
(en)
|
2002-06-21 |
2011-07-18 |
Novo Nordisk Healthcare Ag |
Pegylated factor VII glycoforms
|
US7122189B2
(en)
|
2002-08-13 |
2006-10-17 |
Enzon, Inc. |
Releasable polymeric conjugates based on aliphatic biodegradable linkers
|
US7087229B2
(en)
|
2003-05-30 |
2006-08-08 |
Enzon Pharmaceuticals, Inc. |
Releasable polymeric conjugates based on aliphatic biodegradable linkers
|
BR0314107A
(en)
|
2002-09-11 |
2005-07-19 |
Fresenius Kabi De Gmbh |
Production method of hydroxyalkyl starch derivatives
|
EP1681303B1
(en)
|
2002-09-11 |
2013-09-04 |
Fresenius Kabi Deutschland GmbH |
HASylated polypeptides, especially HASylated erythropoietin
|
DE02020425T1
(en)
|
2002-09-11 |
2004-07-15 |
Fresenius Kabi Deutschland Gmbh |
Hasylated polypeptides, especially hasylated erythropoietin
|
US20040062748A1
(en)
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
CA2509260C
(en)
|
2002-12-31 |
2012-10-02 |
Nektar Therapeutics Al, Corporation |
Maleamic acid polymer derivatives and their bioconjugates
|
US7432330B2
(en)
|
2002-12-31 |
2008-10-07 |
Nektar Therapeutics Al, Corporation |
Hydrolytically stable maleimide-terminated polymers
|
SI1596887T1
(en)
|
2003-02-26 |
2022-05-31 |
Nektar Therapeutics |
Polymer-factor viii moiety conjugates
|
US7623892B2
(en)
|
2003-04-02 |
2009-11-24 |
Palm, Inc. |
System and method for enabling a person to switch use of computing devices
|
CA2521784C
(en)
|
2003-04-08 |
2012-03-27 |
Yeda Research And Development Co. Ltd. |
Reversible pegylated drugs
|
WO2006127896A2
(en)
|
2005-05-25 |
2006-11-30 |
Neose Technologies, Inc. |
Glycopegylated factor ix
|
US20070026485A1
(en)
|
2003-04-09 |
2007-02-01 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
EP1653991A2
(en)
|
2003-08-08 |
2006-05-10 |
Fresenius Kabi Deutschland GmbH |
Conjugates of a polymer and a protein linked by an oxime linking group
|
CN1832762B
(en)
*
|
2003-08-08 |
2012-09-05 |
弗雷泽纽斯卡比德国有限公司 |
Conjugates of hydroxyalkyl starch and g-csf
|
JP2007501812A
(en)
|
2003-08-08 |
2007-02-01 |
ノボ ノルディスク アクティーゼルスカブ |
Synthesis and application of new structurally well-defined branched polymers as binders for peptides
|
WO2005016974A1
(en)
|
2003-08-12 |
2005-02-24 |
Lipoxen Technologies Limited |
Sialic acid derivatives for protein derivatisation and conjugation
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
WO2005055950A2
(en)
|
2003-12-03 |
2005-06-23 |
Neose Technologies, Inc. |
Glycopegylated factor ix
|
US20070254836A1
(en)
|
2003-12-03 |
2007-11-01 |
Defrees Shawn |
Glycopegylated Granulocyte Colony Stimulating Factor
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
KR101439880B1
(en)
|
2004-01-08 |
2014-09-12 |
라티오팜 게엠베하 |
O-linked glycosylation of peptides
|
WO2005092369A2
(en)
|
2004-03-11 |
2005-10-06 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyethyl starch and erythropoietin
|
GB0412181D0
(en)
*
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
US20090292110A1
(en)
|
2004-07-23 |
2009-11-26 |
Defrees Shawn |
Enzymatic modification of glycopeptides
|
JP2008507990A
(en)
|
2004-08-02 |
2008-03-21 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
Conjugate of FVII
|
WO2006016168A2
(en)
|
2004-08-12 |
2006-02-16 |
Lipoxen Technologies Limited |
Sialic acid derivatives
|
US8268967B2
(en)
|
2004-09-10 |
2012-09-18 |
Novo Nordisk A/S |
Glycopegylated interferon α
|
PL1824988T3
(en)
|
2004-11-12 |
2018-01-31 |
Bayer Healthcare Llc |
Site-directed modification of fviii
|
JP5425398B2
(en)
|
2004-12-22 |
2014-02-26 |
アンブレツクス・インコーポレイテツド |
Compositions comprising unnatural amino acids and polypeptides, methods relating to unnatural amino acids and polypeptides, and uses of unnatural amino acids and polypeptides
|
MX2007007877A
(en)
|
2004-12-27 |
2007-08-21 |
Baxter Int |
Polymer-von willebrand factor-conjugates.
|
JP2008526864A
(en)
|
2005-01-06 |
2008-07-24 |
ネオス テクノロジーズ インコーポレイテッド |
Sugar linkage using sugar fragments
|
MX2007009598A
(en)
*
|
2005-02-08 |
2008-03-10 |
Queensland Inst Med Res |
Immunogenic molecules.
|
EP2279758B1
(en)
|
2005-06-16 |
2015-02-25 |
Nektar Therapeutics |
Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
|
JP5335422B2
(en)
|
2005-06-17 |
2013-11-06 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
Selective reduction and derivatization of engineered proteins containing at least one unnatural cysteine
|
US20090017007A1
(en)
|
2005-08-26 |
2009-01-15 |
Maxygen Holdings Ltd. |
Liquid factor vii composition
|
JP2009506096A
(en)
*
|
2005-08-30 |
2009-02-12 |
ノボ ノルディスク ヘルス ケア アーゲー |
Liquid preparation of pegylated growth hormone
|
JP5405122B2
(en)
|
2005-12-21 |
2014-02-05 |
ワイス・エルエルシー |
Low viscosity protein formulations and uses thereof
|
EP1974025A4
(en)
*
|
2006-01-19 |
2009-03-11 |
Ambrx Inc |
Non-natural amino acid polypeptides having modulated immunogenicity
|
KR20080108147A
(en)
|
2006-03-31 |
2008-12-11 |
백스터 인터내셔널 인코포레이티드 |
Pegylated factor viii
|
US7645860B2
(en)
|
2006-03-31 |
2010-01-12 |
Baxter Healthcare S.A. |
Factor VIII polymer conjugates
|
EP2089052A4
(en)
|
2006-05-24 |
2011-02-16 |
Peg Biosciences |
Peg linker compounds and biologically active conjugates thereof
|
US7939632B2
(en)
|
2006-06-14 |
2011-05-10 |
Csl Behring Gmbh |
Proteolytically cleavable fusion proteins with high molar specific activity
|
US8097437B2
(en)
|
2006-07-13 |
2012-01-17 |
Serum Institute Of India Ltd. |
Highly pure polysialic acid and process for preparation thereof
|
EP2059527B1
(en)
*
|
2006-09-01 |
2014-12-03 |
Novo Nordisk Health Care AG |
Modified glycoproteins
|
EP2054521A4
(en)
|
2006-10-03 |
2012-12-19 |
Novo Nordisk As |
Methods for the purification of polypeptide conjugates
|
WO2008058547A2
(en)
*
|
2006-11-17 |
2008-05-22 |
Nya Hamlet Pharma Ab |
Alpha-lactalbumin composition
|
BRPI0720282B8
(en)
|
2006-12-15 |
2021-05-25 |
Baxalta GmbH |
protein construction, pharmaceutical composition, and kit
|
WO2008083346A1
(en)
|
2006-12-28 |
2008-07-10 |
Ambrx, Inc. |
Phenazine and quinoxaline substituted amino acids and polypeptides
|
EP2099475B1
(en)
|
2007-01-03 |
2016-08-24 |
Novo Nordisk Health Care AG |
Subcutaneous administration of coagulation factor viia-related polypeptides
|
WO2008119815A1
(en)
|
2007-04-02 |
2008-10-09 |
Novo Nordisk A/S |
Subcutaneous administration of coagulation factor ix
|
WO2009000522A1
(en)
|
2007-06-26 |
2008-12-31 |
Baxter International Inc. |
Hydrolysable polymeric fmoc-linker
|
CA2690440A1
(en)
|
2007-07-03 |
2009-01-08 |
Children's Hospital & Research Center At Oakland |
Oligosialic acid derivatives, methods of manufacture, and immunological uses
|
US20100239517A1
(en)
|
2007-10-09 |
2010-09-23 |
Stephen Brocchini |
Novel conjugated proteins and peptides
|
EP2070951A1
(en)
|
2007-12-14 |
2009-06-17 |
Fresenius Kabi Deutschland GmbH |
Method for producing a hydroxyalkyl starch derivatives with two linkers
|
JP5647899B2
(en)
|
2008-01-08 |
2015-01-07 |
ラツィオファルム ゲーエムベーハーratiopharm GmbH |
Glycoconjugation of polypeptides using oligosaccharyltransferase
|
US20130189239A1
(en)
|
2008-02-27 |
2013-07-25 |
Novo Nordisk A/S |
Conjugated Factor VIII Molecules
|
NZ588854A
(en)
|
2008-04-24 |
2011-12-22 |
Celtic Pharma Peg Ltd |
Factor ix-polyethylene conjugates with extended half-lives
|
WO2009141418A1
(en)
|
2008-05-23 |
2009-11-26 |
Novo Nordisk A/S |
Formulations of peg-functionalised serine proteases with high concentrations of an aromatic preservative
|
EP2285401A1
(en)
|
2008-05-23 |
2011-02-23 |
Novo Nordisk Health Care AG |
Low viscosity compositions comprising a pegylated gla-domain containing protein
|
US20110286988A1
(en)
|
2008-06-04 |
2011-11-24 |
Bayer Healthcare Llc |
FVIII Muteins for Treatment of Von Willebrand Disease
|
ES2536882T3
(en)
|
2008-07-21 |
2015-05-29 |
Polytherics Limited |
New reagents and method of conjugation of biological molecules
|
CA2740793A1
(en)
|
2008-11-03 |
2010-06-03 |
Haiyan Jiang |
Method for the treatment of hemophilia
|
US20120121613A1
(en)
|
2009-01-19 |
2012-05-17 |
Bayer Healthcare Llc |
Protein conjugate having an endopeptidase- cleavable bioprotective moiety
|
WO2010102886A1
(en)
|
2009-02-19 |
2010-09-16 |
Novo Nordisk A/S |
Modification of factor viii
|
US9005598B2
(en)
|
2009-03-04 |
2015-04-14 |
Polytherics Limited |
Conjugated proteins and peptides
|
US20100330033A1
(en)
|
2009-04-16 |
2010-12-30 |
Nian Wu |
Protein-carrier conjugates
|
WO2010140148A1
(en)
|
2009-06-01 |
2010-12-09 |
Yeda Research And Development Co . Ltd |
Prodrugs containing albumin binding probe
|
EA201290069A1
(en)
|
2009-07-31 |
2012-07-30 |
Байер Хелскер Ллс |
MODIFIED POLYPEPTIDES OF FACTOR IX AND THEIR APPLICATION
|
DE102009028526A1
(en)
|
2009-08-13 |
2011-02-24 |
Leibniz-Institut Für Polymerforschung Dresden E.V. |
Process for the modification and functionalization of saccharides
|
US20120178914A1
(en)
|
2009-09-25 |
2012-07-12 |
Vybion, Inc. |
Polypeptide modification
|
CN102639553A
(en)
|
2009-11-24 |
2012-08-15 |
诺沃—诺迪斯克保健股份有限公司 |
Method of purifying pegylated proteins
|
JP5826772B2
(en)
*
|
2010-02-16 |
2015-12-02 |
ノヴォ ノルディスク アー/エス |
Conjugate protein
|
WO2011101242A1
(en)
|
2010-02-16 |
2011-08-25 |
Novo Nordisk A/S |
Factor viii molecules with reduced vwf binding
|
GB201007357D0
(en)
|
2010-04-30 |
2010-06-16 |
Leverton Licence Holdings Ltd |
Conjugated factor VIII
|
GB201007356D0
(en)
|
2010-04-30 |
2010-06-16 |
Leverton Licence Holdings Ltd |
Conjugated factor VIIa
|
KR101969601B1
(en)
|
2010-07-30 |
2019-04-17 |
박스알타 인코퍼레이티드 |
Nucleophilic catalysts for oxime linkage
|
EP2640483A1
(en)
|
2010-11-15 |
2013-09-25 |
Biogen Idec Inc. |
Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
|
EP2729161B1
(en)
|
2011-07-08 |
2018-12-19 |
Bioverativ Therapeutics Inc. |
Factor viii chimeric and hybrid polypeptides, and methods of use thereof
|